ACM
HEPA

Altium Capital Management’s Hepion Pharmaceuticals HEPA Stock Holding History

Altium Capital Management’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-446
Closed -$883K – 136
2021
Q2 		$883K Buy
+446
New +$816K 0.2% 114

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AMC
Asset Management Corp Northbrook, Illinois $128M AUM 6.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Altium Capital Management's HEPA Position: Q3 2021 in Review

Altium Capital Management sold out of Hepion Pharmaceuticals (HEPA) in Q3 2021, closing a stake of 446 shares — an estimated $883K sold.

Altium Capital Management first reported a position in HEPA in Q2 2021 and held it in 1 quarter. The position peaked at $883K in Q2 2021. 37 funds tracked by Wall St. Rank hold HEPA as of Q3 2021.

  • Altium Capital Management reported no remaining Hepion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Altium Capital Management sold 446 Hepion Pharmaceuticals shares in Q3 2021, an estimated $883K.
  • Altium Capital Management first reported a position in Hepion Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Altium Capital Management's Hepion Pharmaceuticals position peaked at $883K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q3 2021.

Based on Altium Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.